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RIG-I and MDA5 detect viral RNA in the cytoplasm
and activate signaling cascades leading to the pro-
duction of type-I interferons. RIG-I is activated
through sequential binding of viral RNA and unan-
chored lysine-63 (K63) polyubiquitin chains, but
how polyubiquitin activates RIG-I and whether
MDA5 is activated through a similar mechanism
remain unresolved. Here, we showed that the CARD
domains of MDA5 bound to K63 polyubiquitin and
that this binding was essential for MDA5 to activate
the transcription factor IRF3. Mutations of conserved
residues in MDA5 and RIG-I that disrupt their ubiqui-
tin binding also abrogated their ability to activate
IRF3. Polyubiquitin binding induced the formation
of a large complex consisting of four RIG-I and four
ubiquitin chains. This hetero-tetrameric complex
was highly potent in activating the antiviral signaling
cascades. These results suggest a unified mecha-
nism of RIG-I and MDA5 activation and reveal a
unique mechanism by which ubiquitin regulates cell
signaling and immune response.
INTRODUCTION
Innate immunity is an evolutionarily conserved form of host
defense mechanism found in most multicellular organisms. The
detection of pathogens by the innate immune system involves
recognition of pathogen-associatedmolecular patterns (PAMPs)
by a set of host pattern recognition receptors (PRRs) (Kawai and
Akira, 2011). After virus infection, viral RNA is recognized in the
endosome in specialized cells by membrane-bound Toll-like
receptors (TLRs) and in the cytosol of vertebrate cells by RIG-I
like receptors (RLRs), which include RIG-I, MDA5, and LGP2
(Yoneyama et al., 2004). Upon viral recognition, RIG-I and
MDA5 activate the mitochondrial adaptor protein MAVS (also
known as IPS-1, VISA, or CARDIF) and initiate downstream
signaling pathways to activate the transcription factors NF-kB
and IRF3, which regulate the production of type I interferons(e.g., IFN-a and IFN-b) and proinflammatory cytokines (Rehwin-
kel and Reis e Sousa, 2010).
All three members of the RLRs share highly conserved domain
structures, including a DExD/H box helicase domain and a
C-terminal RNA binding domain (CTD). RIG-I and MDA5, but
not LGP2, have at their N-termini two caspase activation and
recruitment domains (CARDs) in tandem that mediate signaling
to downstream adaptor proteins. RIG-I and MDA5 have been
shown to play a key role in type-I IFN induction after RNA virus
infection, whereas LGP2 is thought to play a regulatory role.
Current models suggest that, in the absence of viral RNA,
RIG-I adopts an autoinhibited conformation. The binding of viral
RNA, which contains 50-triphosphate (50-ppp) and certain duplex
structures, to the CTD and helicase domains of RIG-I induces
an ATP-dependent conformational change that exposes the
CARDs (Kowalinski et al., 2011). RIG-I then translocates on the
viral RNA, while the CARDs interact with the ubiquitin ligase
TRIM25, which functions together with the ubiquitin E2 complex
Ubc13-Uev1A to catalyze the synthesis of K63 polyubiquitin
chains (Gack et al., 2007; Myong et al., 2009). We have recently
found that free K63 polyubiquitin chains, which are not conju-
gated to any cellular protein, can bind to RIG-I CARD domains
(Zeng et al., 2010) and that this binding is important for the
activation of IRF3 and the induction of IFNb. Thus, RIG-I activa-
tion requires sequential binding of viral RNA to the CTD followed
by the binding of endogenous K63 polyubiquitin chains to the
N-terminal CARDs. However, how polyubiquitin binding leads
to RIG-I activation is an important question that remains
unresolved.
Although MDA5 is known to play crucial roles in immune
responses against many RNA viruses, especially picornaviruses
(Kato et al., 2006), little is known about how MDA5 is activated
and how it activates the downstream pathways leading to IFN
production. The C terminus of MDA5 is distinct from the CTD
of RIG-I and it does not bind 50-pppRNA (Takahasi et al.,
2009). Although long double-stranded RNA analog poly[I:C]
has been shown to induce IFN-b in an MDA5-dependent manner
(Kato et al., 2008), the physiological ligand ofMDA5 has not been
defined. A previous study found that RIG-I, but not MDA5, is
ubiquitinated by TRIM25, and that a putative ubiquitination site
of RIG-I (K172) is not conserved in MDA5, raising the question
of whether ubiquitination plays any role in MDA5 activation
(Gack et al., 2007).Immunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc. 959
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Mechanism of RIG-I and MDA5 Activation by UbiquitinIn this study, we showed that MDA5 can activate IRF3 in
a cell-free system and that MDA5 CARDs bind to K63 polyubi-
quitin chains. Mutations in the conserved residues of MDA5
and RIG-I CARDs that disrupt their binding to ubiquitin chains
also impaired their ability to activate IRF3 and induce IFNb.
Further, using RIG-I CARDs as a model, we demonstrated that
K63 polyubiquitin binding induced oligomerization of RIG-I
in vitro and in virus-infected cells. Irrespective of ubiquitin chain
lengths, RIG-I forms a tetramer that is highly active in signaling
to IRF3.
RESULTS
Ubiquitin-Dependent Activation of the MDA5 Signaling
Cascade in a Cell-Free System
We have previously shown that RIG-I N terminus containing the
CARDs [RIG(N)] binds K63 polyubiquitin chains, and that this
binding triggers a signaling cascade that leads to the activation
of IRF3 and IKK in a cell-free system consisting of mitochondria
and cytosolic extracts (Zeng et al., 2010). To investigate whether
MDA5 CARDs [MDA5(N)] could also activate IRF3 through a
similar mechanism, we expressed GST-MDA5(N) in E. coli, puri-
fied it, and incubated it in a ubiquitination reaction containing E1,
Ubc13-Uev1A (E2), TRIM25 (E3), and ubiquitin in the presence or
absence of ATP (Figures 1A and 1B). Afterward, the reaction
mixtures were incubated with mitochondria (P5) and cytosolic
extracts (S5) together with 35S-IRF3 and ATP and subsequently
subjected to native gel electrophoresis so that IRF3 dimerization
could be detected. Like RIG-I(N), MDA5(N) was capable of
causing IRF3 dimerization after the ubiquitination reaction (Fig-
ure 1B). To determine whether ubiquitination of RIG-I(N) or
MDA5(N) was involved in its activation, we carried out the ubiq-
uitination reaction as described in Figure 1B except that
GST-RIG-I(N) or MDA5(N) was omitted from the reaction. The
thio-modifying agent N-ethymaleimide (NEM) was added to the
reaction mixture to inactivate E1 and E2, and then the reaction
mixture, which contained mostly unanchored K63 polyubiquitin
chains (Xia et al., 2009), was incubated with GST-RIG-I(N) or
GST-MDA5(N). Both GST-RIG-I(N) and GST-MDA5(N) gained
the ability to activate IRF3 after incubation with K63 polyubiquitin
chains (Figure 1C). We have previously shown that unanchored
K63 ubiquitin chains could directly activate RIG-I(N) (Zeng
et al., 2010). Similarly, incubation of K63 chains containing four
or more ubiquitin with GST-MDA5(N) led to IRF3 activation in
the in vitro assay (Figure 1D). In contrast, K48 ubiquitin chains
had no activity. Interestingly, Ub4 containing the K48-K63-
K48 mixed linkage weakly stimulated GST-RIG-I(N) and GST-
MDA5(N), whereas Ub4 containing the K63-K48-K63 linkage
was inactive, hinting that the K63 linkage in the center of Ub4
may be important (Figure 1D, lanes 14 and 15). Linear Ub4, in
which the N-terminal methionine of one ubiquitin is conjugated
by the C terminus of the preceding ubiquitin, did not activate
MDA5(N) (Figure 1E).
Full-length MDA5 is activated by long poly[I:C] as well as by
undefined ligands associated with certain RNA viruses such as
those of picornaviridae (Kato et al., 2006). To determine whether
full-length MDA5 could lead to IRF3 activation in the in vitro
reconstitution system, we tested MDA5 expressed and purified
from E. coli. Similar to RIG-I, incubation of MDA5 with poly[I:C],960 Immunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc.ATP and K63 polyubiquitin chains led to strong activation of
IRF3 in the cell-free system (Figure 1F).
RIG-I and MDA5 CARD Domains Bind K63 Polyubiquitin
Chains
CARD domains belong to the death domain (DD) superfamily,
which also includes the death domain (DD), death effector
domain (DED), and pyrin domain (PYD) subfamilies (Park et al.,
2007).Many proteins of the DD superfamily are involved in immu-
nity, inflammation, and cell death. Our finding that RIG-I CARDs
bind to K63 polyubiquitin chains (Zeng et al., 2010) raises the
question of whether the CARD or DD domains of some other
proteins are also ubiquitin-binding domains (UBDs). To begin
to address this question, we carried out bioinformatics analysis
of the CARD domain subfamily (Figure S1A available online).
CARD domain subfamily sequences were collected by PSI-
BLAST. Clustering analysis based on sequence homology
shows that the CARD domains of RIG-I (two CARD domains),
MDA5 (two CARD domains) and MAVS form a distinct cluster
that is distantly related to other CARD domains, such as those
present in NOD1, NOD2, and RIP2, which are important in innate
immunity. Although all DD superfamily domains share a con-
served six-helical bundle fold, the CARD domain subfamily is
also distinct from DD and DED subfamilies in structure-based
homology analysis (Figure S1B).
Our previous study showed that both CARD domains of RIG-I
are required for binding to K63 polyubiquitin chains and the
single CARD of MAVS does not bind to these chains (Zeng
et al., 2010). Similar to GST-RIG-I(N), GST-MDA5(N) bound to
K63 polyubiquitin chains, but not linear or K48 polyubiquitin
chains (Figure 2A and Figure S1C). In contrast, the CARD of
NOD1, tandemCARDs of NOD2, and tandemDEDs of caspase 8
did not exhibit detectable ubiquitin chain binding activity (Fig-
ures S1D and S1E). Although these results do not exclude the
possibility that some other proteins in the DD superfamily can
bind ubiquitin chains, they suggest that the CARD domains of
RIG-I and MDA5 are unique in their ability to bind specifically
to K63 polyubiquitin chains.
To determine whether MDA5 binds to endogenous, unan-
chored, K63-linked, polyubiquitin chains in cells, weusedaprevi-
ously developed method to isolate these polyubiquitin chains
(Figure 2B, left) (Zeng et al., 2010). In this method, we overex-
pressed GST-MDA5(N) in HEK293T cells, prepared cell lysates
in which most of the cellular deubiquitinating enzymes (DUBs)
were inactivated by NEM, and then used glutathione-Sepharose
to pull down GST-MDA5(N) as well as the associated endoge-
nous ubiquitin chains. The isolated complexes were heated at
75C to denaturemost of the proteins while sparing free ubiquitin
chains which are relatively heat resistant. After centrifugation to
remove denatured proteins, the supernatant containing the ubiq-
uitin chains was incubated with recombinant GST-RIG-I(N) or
GST-MDA5(N) protein to measure IRF3 activation. As shown in
Figure 2B, the heat-resistant supernatant from the cells express-
ing GST-RIG-I(N) or GST-MDA5(N), but not GST, contained the
activity that, when incubated with fresh GST-RIG-I(N) or GST-
MDA5(N) protein again, stimulated IRF3 dimerization in the
in vitro assay. This activity was destroyed by the DUBs
isopeptidase T (IsoT) and CYLD (Figure 2C), which specifi-
cally cleave unanchored and K63 linked polyubiquitin chains,
Figure 1. MDA5 Activates IRF3 in a Cell-Free System through a Ubiquitin-Dependent Mechanism
(A) Diagrams of RIG-I and MDA5 (left); Coomassie blue stained gels of their N-terminal CARD domains expressed in and purified from E. coli (right).
(B) GST-RIG-I(N) or GST-MDA5(N) was incubated with ubiquitination components as shown in the diagram. Aliquots of the reaction mixtures were further
incubated with mitochondria (P5) and cytosolic extracts (S5) together with 35S-IRF3 and ATP. IRF3 dimerization was analyzed by native gel electrophoresis.
(C) Similar to (B), except that RIG-I(N) or MDA5(N) was incubated with polyubiquitination mixtures in which E1 and E2 had been inactivated by NEM.
(D and E) Similar to (C), except that RIG-I(N) or MDA5(N) was incubated with unanchored ubiquitin chains of different lengths and linkages as indicated.
(F) Similar to (C), except that full-length (FL) RIG-I or MDA5 was incubated with K63-Ub6, MgATP, and poly[I:C] as indicated. Shown on the left are Coomassie
blue stained gels of RIG-I and MDA5 proteins. Results shown are representatives of three experiments.
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Figure 2. K63 Polyubiquitin Chains Bind to and Activate MDA5
(A) GST or GST-MDA5(N) was incubated with polyUb chains containing K63, K48, or linear linkage and then pulled down with glutathione beads and
immunoblotted with indicated antibodies. Input represents 10% of polyubiquitin used for GST pulldown (GST-PD) experiments.
(B) Endogenous polyUb chains in HEK293T cells were isolated using the procedure shown in the diagram (left). After centrifugation, the supernatant containing
the ubiquitin chains was incubated with GST-RIG-I(N) or GST-MDA5(N), which were then incubated with mitochondria (P5) and cytosol (S5) to measure IRF3
activation.
(C) Endogenous polyUb chains associated with RIG-I(N) or MDA5(N) were isolated as in (B) and then incubated with GST-RIG-I(N) followed by IsoT or CYLD
treatment, or in reverse order, before IRF3 dimerization assay. Parallel experiments were carried out using free K63 polyUb chains as controls (lanes 13-18).
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Mechanism of RIG-I and MDA5 Activation by Ubiquitinrespectively (Reyes-Turcu et al., 2006; Xia et al., 2009). Prein-
cubation of the heat-resistant supernatant with GST-RIG-I(N)
rendered the activity resistant to IsoT and CYLD, indicating
that GST-RIG-I(N) protected unanchored K63 polyubiquitin
chains from degradation by the DUBs. Taken together, these
results show that MDA5 CARDs bind endogenous unanchored
K63 polyubiquitin chains in cells.
EMCV RNA Induces the Association of MDA5 with
Endogenous Polyubiquitin Chains
Encephalomyocarditis virus (EMCV) is a picornavirus known to
induce type-I interferons throughMDA5 (Kato et al., 2006). Infec-
tion of murine embryonic fibroblasts (MEF) with EMCV induced
IFN-b, and this induction was abolished by the knockdown of
MDA5 with a lentiviral shRNA vector (Figure S1F). We found
that total RNA from EMCV-infected HEK293T cells induced
IFNb much more strongly (300-fold higher) than EMCV infec-
tion (Figure S1G), suggesting that some viral proteins might
inhibit IFN-b induction by the viral RNA. shRNA against MDA5
blocked IFN-b induction by EMCV RNA, but not Sendai virus
(SeV) RNA, which is known to activate RIG-I. HEK293T cells
stably expressing MDA5, but not GFP control, also produced
IFN-b in response to transfection of EMCV RNA (Figure 2D). To
determine whether EMCV RNA stimulates the association of
unanchored K63 polyubiquitin chains with full-length MDA5 in
cells, we immunoprecipitated MDA5 from HEK293T cells trans-
fected with EMCV RNA, prepared the heat-resistant supernatant
as described above, and then measured its activity in the
presence or absence of GST-RIG-I(N) (Figure 2E). The superna-
tant prepared from EMCV-transfected cells contained IRF3-
stimulatory activity that is sensitive to IsoT or CYLD treatment
but protected from these DUBs by preincubation with GST-
RIG-I(N). These results suggest that MDA5 associates with
endogenous unanchored K63 polyubiquitin chains in response
to stimulation with EMCV RNA.
K63Polyubiquitination Is Required to Activate theMDA5
Pathway
To further investigate the role of K63 polyubiquitination in MDA5
activation by EMCV RNA in cells, we used a previously estab-
lished human U2OS cell line in which the K63-specific ubiquitin
E2 Ubc13 could be efficiently knocked down with tetracycline-
inducible shRNA (Xu et al., 2009). Ubc13 depletion blocked
IFN-b induction by EMCV RNA (Figure 2F). Similarly, MEF cells
from Trim25 knockout mice failed to induce IFN-b in response
to EMCV RNA transfection (Figure 2G). Previously, we also
established U2OS cell lines in which endogenous ubiquitin could(D) HEK293T cells stably expressing GFP (control) or MDA5 were transfected wi
(E) Similar to (B) and (C), except that endogenous polyUb chains associated wit
pressing MDA5-Flag. The polyUb chains were incubated with GST-RIG-I(N) and I
(S5) for measuring IRF3 dimerization.
(F) U2OS integrated with tetracycline-inducible shRNA against Ubc13 (shUbc13)
was measured by qPCR.
(G) WT or Trim25-deficient (KO) MEF cells were transfected with indicated RNA.
(H and I) Similar to (F), except that U2OS cells stably expressing tetracycline-in
ubiquitin was replaced with K63R ubiquitin (shUb/K63R, right) were transfected
(J) RNA transfection of U2OS cells was carried out as in (H) and (I), and then we
measure IRF3 dimerization. Aliquots of the mitochondrial extracts were immunob
experiments.be knocked down by shRNA and replaced with wild-type or
K63R mutant ubiquitin in a tetracycline-inducible manner (Xu
et al., 2009). IFN-b induction by EMCV RNA was largely blocked
in cells expressing ubiquitin shRNA and significantly impaired in
cells expressing K63R ubiquitin (Figures 2H and 2I). To test
whether MAVS activation is impaired by a defect in K63 polyubi-
quitination, we isolated the mitochondria from EMCV RNA trans-
fected cells and tested their ability to stimulate IRF3 dimerization
in the in vitro assay. Figure 2J shows that mitochondria from cells
expressing shRNA against Ubc13 or Ub and those in which
endogenous ubiquitin was replaced with K63R ubiquitin failed
to activate IRF3. Taken together, these results suggest that
MAVS activation by MDA5 in response to EMCV RNA is depen-
dent on K63 polyubiquitination.
Both CARD Domains of RIG-I and MDA5 Are Important
for Polyubiquitin Binding
To delineate the regions in RIG-I andMDA5 that are important for
ubiquitin binding and IRF3 activation, we generated a series of
mutants with progressive deletion of amino acids from the
N terminus of the first CARD or the C terminus of the second
CARD (Figures S2A and S2C). These mutants were expressed
in E. coli as GST fusion proteins and affinity purified. The purified
proteins were tested for their binding to K63 polyubiquitin chains
and their ability to activate IRF3 in the cell-free system (Fig-
ures S2B and S2D). Overall, with both RIG-I(N) and MDA5(N),
there was a good correlation between their ability to bind K63
ubiquitin chains and their ability to activate IRF3. In particular,
a RIG-I fragment containing residues 6-188 was capable of
binding to K63 polyubiquitin chains and activating IRF3, and
further removal of two amino acids from the C terminus of the
second CARD (6-186) abolished both activities (compare lanes
10 and 11 in Figure S2B). The truncation of the first 7 amino acids
(8-190) also significantly impaired RIG-I’s activities (compare
lanes 7 and 8 in Figure S2B). Similarly, the deletion of just five
amino acids from the second CARD of MDA5 destroyed its ubiq-
uitin binding as well as its ability to activate IRF3 (compare lanes
2 and 3 in Figure S2D).
Polyubiquitin Binding Is Essential for RIG-I and MDA5
to Activate IRF3 and Induce IFN-b
To further define the relationship between ubiquitin binding and
IRF3 activation by RIG-I and MDA5, we sought to identify key
residues in the CARD domains that are important for their func-
tions. Sequence alignment of the CARD domains of RIG-I from
human, mouse, and zebrafish, as well as those of human and
mouse MDA5, revealed several highly conserved residuesth indicated RNA. IFN-b induction was measured by quantitative PCR (qPCR).
h MDA5 were isolated from EMCV RNA-transfected HEK293T cells stably ex-
soT or CYLD in the indicated order and then with mitochondria (P5) and cytosol
were treated with or without tetracycline (Tet). IFN-b induction by EMCV RNA
IFN-b was measured by qPCR.
ducible shRNA against ubiquitin (shUb, left), and those in which endogenous
with EMCV RNA. Afterward, IFN-b was measured by qPCR.
isolated mitochondria (P5) and incubated them with cytosolic extracts (S5) to
lotted with a MAVS antibody. Error bars represent variation range of duplicate
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Figure 3. Ubiquitin Binding Is Essential for RIG-I and MDA5 Activation
(A) Sequence alignment of the N-termini of RIG-I andMDA5 from human (h) andmouse (m) aswell as zebrafish (f) RIG-I N terminus. Asterisks indicate the residues
to be mutated in this study. Shown on the right are the GST-RIG-I(N) mutant proteins expressed in and purified from E. coli.
(B) Point mutants of RIG-I(N) were incubated with K63 polyUb and then analyzed by GST pull-down and IRF3 dimerization assays.
(C) Full-length RIG-I WT and mutants were stably expressed in RIG-I knockout (KO) MEF cells. The reconstituted cells were infected with SeV for the indicated
time, and then IFN-bwas measured by qPCR (left). Mitochondrial fractions (P5) were prepared from the virus-infected cells, and MAVS activity was measured in
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Mechanism of RIG-I and MDA5 Activation by Ubiquitin(Figure 3A). These residues were mutated (highlighted by
asterisk) and GST fusion proteins containing these mutations
were expressed in E. coli and affinity purified. Strikingly, among
ten point mutants of RIG-I(N) tested, eight mutations (L58A, G68/
W69A, D93A, L131A, K164A, W167A, P112A, and E135A) abol-
ished RIG-I(N)’s binding to K63 polyubiquitin chains as well as its
ability to activate IRF3 (Figure 3B). One mutation, K164R, led to
reduced ubiquitin chain binding as well as weakened IRF3 acti-
vation (Figure 3B, lane 8 on the left panel). Another mutant,
D122A, bound normally to ubiquitin chains but had reduced
ability to activate IRF3 (Figure 3B, lanes 10–12 on the right panel).
This result suggests that after RIG-I binds to K63 polyubiquitin
chains, the D122A mutation impairs its ability to activate the
downstream signaling cascade, possibly by affecting the inter-
action between RIG-I and MAVS.
The crystal structures of RIG-I and its double-stranded RNA
bound forms have been solved (reviewed by O’Neill and Bowie,
2011). These structures show that the tandem CARDs of RIG-I
interact with each other (Kowalinski et al., 2011). Furthermore,
the second CARD interacts with a unique insertion domain
(HEL2i) between helicase domains 1 and 2; this interaction
may prevent the binding of CARDs to polyubiquitin chains in
the absence of viral infection. Interestingly, modeling of human
RIG-I CARDs based on the structure of the duck RIG-I CARDs
shows that several residues whose substitutions impair ubiquitin
binding are mapped to the surface of CARD2 or at the junction
between CARD1 and CARD2 (Figures S2E and S2F). These resi-
dues include D93, P112, D122, E135, K164, and K172.
We have recently shown that MAVS undergoes a massive
prion-like aggregation on the mitochondrial membrane in re-
sponse to viral infection of cells or upon the contact of mito-
chondria with the RIG-I complex containing K63 polyubiquitin
chains in vitro (Hou et al., 2011). In the presence of K63 polyubi-
quitin chains, the aggregation ofMAVS induced byWTGST-RIG-
I(N) was detected by semi-denaturing detergent agarose gel
electrophoresis (SDD-AGE), which is commonly used for detect-
ing prion-like aggregates (Figure S2G) (Alberti et al., 2009). In
contrast, RIG-I mutants containing D93A or six-lysine mutations
(K99, 169, 172, 181, 190, and 193; termed6KR), both ofwhich are
defective in ubiquitin binding, failed to induceMAVSaggregation.
The D122A mutant also had a greatly reduced ability to cause
MAVS aggregation, which probably explains the reduced ability
of this mutant to activate IRF3 despite its normal binding to K63
polyubiquitin (Figure S2G, lanes 11-14).
To determine whether mutations that abrogate the ubiquitin
binding of RIG-I also affect its ability to induce IFN-b in cells,
we used a lentiviral vector to express full-length RIG-I or its
mutated forms in RIG-I-deficient MEFs (Figure 3C). The lentiviral
vector contains RIG-I fused to the puromycin-resistant gene
through a picornavirus self-cleaving 2A peptide. The majority
of RIG-I was cleaved from the puromycin-resistant gene pro-
duct, although some fusion protein remained (Figure 3C, upperIRF3 dimerization assay (bottom right). The RIG-I proteins in the reconstituted c
denotes a fusion protein in which RIG-I was not cleaved from the puromycin resis
the lentiviral vector.
(D) Point mutants of MDA5(N) were tested for K63 polyUb binding and IRF3 activ
(E) THP-1 cells stably expressing a lentiviral shRNA vector targeting MDA5 or th
transfected with indicated RNA, and then IFN-b induction was measured by qPCright). The expression of WT RIG-I rescued IFN-b induction in
response to SeV infection. In contrast, L58A, D93A, W167A,
and 6KR mutants failed to induce IFN-b. K164A and K164R
mutants were severely defective in inducing IFN-b, consistent
with the reduced ability of these mutants in activating IRF3
(Figures 3B and 3C). Crude mitochondria isolated from cells re-
constituted with WT RIG-I were able to activate IRF3 in the
in vitro assay if the cells were infected with SeV for 10 hr (Fig-
ure 3C, lower right). In contrast, mitochondria from cells reconsti-
tuted with D93A, K164A, and 6KR mutants of RIG-I had no
activity. Control experiments showed that K164A and 6KR
RIG-I mutants had ATPase activity similar to that of WT RIG-I
(data not shown), suggesting that these mutations do not cause
global misfolding or inactivation of RIG-I. Collectively, these
results indicate that ubiquitin binding of RIG-I is essential for
IFN-b induction by SeV.
Overexpression of GST-RIG-I(N) in HEK293T cells led to
a strong induction of IFN-b-luciferase reporter, providing a simple
assay to rapidly screen the IFNb-inducing activity of a large panel
of RIG-I CARDmutants (Figure S2H). Importantly, all of the ubiq-
uitin-binding defective mutants of RIG-I failed to induce IFN-b in
this assay. These mutants also failed to pull down endogenous
polyubiquitin chains from transfected cells (Figure S2I). Similar
to the in vitro experiments, RIG-I(N)-D122A bound to endoge-
nous ubiquitin chains, but its ability to induce IFN-bwas reduced,
suggesting a defect at a step downstream of ubiquitin binding
(Figures S2H and S2I, left). Three mutants, K146R, E165A
and N166A, which bound to polyubiquitin chains normally,
were also capable of inducing IFN-b (Figures S2H and S2I, right).
Apparently, these mutants were also covalently modified
by ubiquitin chains. In general, there was a good correlation
between RIG-I ubiquitination and IFN-b induction. However, we
have previously shown that the removal of ubiquitin chains
from RIG-I by a deubiquitination enzyme (viral OTU) does not
impair the ability of RIG-I to activate IRF3 (Zeng et al., 2010).
Furthermore, MDA5 does not contain a conserved lysine known
to be ubiquitinated in RIG-I and there is no evidence that MDA5
is ubiquitinated (Gack et al., 2007). We found mutations that
abrogated the ability of MDA5(N) to bind K63 polyubiquitin
chains also impaired its ability to activate IRF3 in vitro and induce
IFN-b in vivo (Figure 3D and Figures S2J and S2K). Moreover,WT
MDA5, but not the ubiquitin-binding defective mutant K174A,
was able to rescue IFN-b induction by EMCV RNA in the human
monocytes THP-1, which had been depleted of endogenous
MDA5 by shRNA (Figure 3E). Taken together, these results
demonstrate that the binding to K63 polyubiquitin chains is
essential for RIG-I and MDA5 to activate IRF3 and induce IFN-b.
Ubiquitin Binding Rescues the Activity of RIG-I CARD
Domain Mutants
Previous studies have shown that K172R mutation of RIG-I
impairs its ubiquitination and IFN-b induction (Gack et al.,ells were immunoblotted with a RIG-I antibody (upper right). The upper band
tance gene product as a result of incomplete self-cleavage of the 2A peptide in
ation as in (B).
ose in which endogenous MDA5 was replaced with WT or K174A MDA5 were
R. Error bars represent variation range of duplicate experiments.
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tion also abrogates the binding of RIG-I to polyubiquitin chains
(Zeng et al., 2010). To determine whether ubiquitin binding or
ubiquitination of RIG-I is important for its signaling functions,
we fused RIG-I CARD mutants to the novel zinc finger (NZF)
domain of NPL4 (Kanayama et al., 2004; Meyer et al., 2002),
which is known to bind polyubiquitin chains (Figure 4A). Remark-
ably, the NZF domain rescues the ability of RIG-I(N)-K172R to
activate IRF3 in the presence of K63, but not K48, polyubiquitin
chains (Figure 4B, compare lanes 6 and 7). The activity of RIG-
I(N) 6KR mutant was also restored by NZF fusion (Figure 4B,
compare lanes 4 and 5). In contrast, a RIG-I(N) mutant contain-
ing 14-lysine mutations (14KR) was inactive even after NZF
fusion, indicating that mutations of some of the lysines affect
RIG-I structure or functions (Figures S3A and S3B). This exper-
iment also rules out the remote possibility that the NZF domain
alone could activate the RIG-I pathway. Interestingly, the NZF
domain restores the binding of K172R and 6KR to both K63
and K48 polyubiquitin chains (Figures 4C and 4D), suggesting
that even when K48 ubiquitin chains are forced to bind to
RIG-I, they cannot activate the pathway. The NZF domain also
restores the ability of RIG-I(N)-6KR and K172R to induce IFN-
b-luciferase in HEK293T cells (Figure 4E, top; Figure S3C).
GST pull down from these cells revealed that RIG-I(N)-6KR-
NZF and RIG-I(N)-K172R-NZF were able to pull down endog-
enous polyubiquitin chains, whereas their ubiquitination was
much weaker than that observed for RIG-I(N)-NZF (Figure 4E,
bottom; Figure S3D). These results provide the direct evidence
that polyubiquitin binding by RIG-I is critical for its signaling
functions.
Ubiquitin-Induced Oligomerization Activates RIG-I
and MDA5
To understand how polyubiquitin binding activates RIG-I, we
performed gel filtration analysis of RIG-I(N) following its incuba-
tion with K63 ubiquitin chains of different lengths. In these
experiments, RIG-I(N) did not contain the GST tag, which could
have confounded the results due to GST-mediated dimerization.
K63-Ub3, -Ub4, -Ub5 and -Ub6, but not Ub, caused a shift of
RIG-I(N) into high molecular weight (HMW) fractions (Figures
5A–5E). Furthermore, the HMW complexes containing RIG-I(N)
and ubiquitin chains are highly potent in activating IRF3 in the
cell-free system. Titration experiments using the RIG-I(N)/Ub4
complex (lane 5 in Figure 5B) showed that the half maximal
effective concentration (EC50) of this complex was 404 pM
(Figure 5F; this is likely an underestimate as it does not take
into account of the dissociation of the complex during the reac-
tion). Incubation of MDA5(N) with K63-Ub6 also caused the
formation of a larger complex composed of both MDA5(N) and
K63-Ub6, which strongly activated IRF3 in the in vitro assay
(Figure 5G).
We estimated the stoichiometry of RIG-I(N):Ub chain complex
by comparing the intensity of Coomassie blue-stained bands
in the complex eluted from the gel filtration column with that
of RIG-I(N) and Ub chains mixed at 2:1, 1:1 and 1:2 ratios (Fig-
ure S4). Such estimates, although imprecise, revealed that
RIG-I(N) and Ub chains had a stoichiometry of approximately
1:1 irrespective of the Ub chain lengths [ratio of RIG-I(N) to
Ub3: 0.8:0.7; to Ub4: 1.4:1.4; to Ub5: 1.2:1.1; to Ub6: 1.1: 0.9].966 Immunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc.Polyubiquitin Binding Promotes the Formation of RIG-I
Tetramer
To more precisely measure the stoichiometry and sizes of
the RIG-I:Ub chain complexes, we performed sedimenta-
tion velocity analytical ultracentrifugation (AUC) (Figure 6).
Calculation of sedimentation coefficients and frictional ratios of
RIG-I(N) and K63-Ub3 alone revealed their molar masses of
24.2 kg/mol and 26.9 kg/mol, respectively, consistent with
their theoretical values (Figure 6A, top; see also Experimental
Procedures). In the sample where RIG-I(N) was incubated with
a large molar excess of K63-Ub3, a faster-sedimenting popula-
tion appeared with a molar mass of 197.5 kg/mol (Figure 6A,
bottom). Multisignal sedimentation velocity analysis (Padrick
et al., 2010) showed that RIG-I(N) and Ub3 in this complex had
a stoichiometry of 1:1, consistent with gel filtration experiments
(Figure S4). Thus, the molar mass and stoichiometry measure-
ments revealed that RIG-I(N) and Ub3 likely formed a complex
containing 4 molecules of RIG-I(N) and four molecules of Ub3.
Similar analyses using K63-Ub4, -Ub5 and -Ub6 suggest that
RIG-I(N) forms complexes with these ubiquitin chains with a
stoichiometry of approximately 4:4 irrespective of chain lengths
(Figures 6B–6D). The distribution of species during the sedimen-
tation process showed few intermediate species, suggesting
that RIG-I(N) and the Ub chains form hetero-tetrameric com-
plexes in a highly cooperative manner.
RNA and Polyubiquitin Induce Oligomerization
and Activation of Full-Length RIG-I
Full-length RIG-I can be activated in vitro when incubated with
RNA ligands and K63 polyubiquitin chains in the presence of
ATP (Zeng et al., 2010). To determine whetherh full-length
RIG-I forms oligomers after binding to K63 polyubiquitin chains,
we carried out gel filtration analyses using purified RIG-I and
K63-Ub6 (Figure 7A; Figure S5A). RIG-I alone eluted from the
column with the peak fraction corresponding to molecular
weight between 75 kDa and 158 kDa (lane 12 in Figure 7A; Fig-
ure S5B), suggesting that it is a monomer. Incubation with
50-pppRNA (containing 135 nucleotides) caused a shift in RIG-I
elution peak to fractions corresponding to 230 kDa, which
may represent a RIG-I dimer bound to the RNA (lanes 10 and
11 in Figure 7A; Figure S5B). Incubation with K63-Ub6 alone
did not change RIG-I distribution because polyubiquitin binding
to RIG-I requires both RNA and ATP (Zeng et al., 2010). Interest-
ingly, when incubated with RNA, K63-Ub6, and ATP, some RIG-I
shifted to HMW fractions that were larger than 400 kDa (Fig-
ure 7A, lanes 2–6). A small fraction of K63-Ub6 also comigrated
with RIG-I to the HMW fractions when the mixture contained
RNA and ATP (Figure S5C, left). Although the signal detected
with the ubiquitin antibody was weaker than that detected with
the RIG-I antibody, semiquantitative immunoblotting suggests
an approximately equal molar ratio of RIG-I to K63-Ub6 in the
HMW complexes (Figure S5C, right). The fractions with molec-
ular weights larger than 600 kDa were most potent in activating
IRF3 in the in vitro assay (Figure 7A and Figure S5C, bottom
panels). Thus, the active HMW complexes could be composed
of RIG-I tetramers with bound RNA and Ub6.
To determine whether RIG-I forms oligomers in cells in
response to viral infection, we established a HEK293T cell line
stably expressing RIG-I-Flag and purified RIG-I-Flag from these
Figure 4. Rescue of Ubiquitination-Defective Mutants of RIG-I with a Heterologous Ubiquitin-Binding Domain
(A) Diagram depicting the NPL4 novel zinc finger (NZF) ubiquitin binding domain and its fusion to RIG-I(N). The bottom panel showsGST-RIG-I(N) mutants and the
NZF fusion proteins.
(B) Indicated proteins were incubated with K63- or K48-ubiquitin chains and then analyzed for their ability to activate IRF3 dimerization in vitro.
(C and D) GST-RIG-I(N) mutant proteins were incubated with K63- (C) or K48- (D) linked ubiquitin chains, and the incubation was followed by GST pull-down
assays.
(E) RIG-I(N)-NZF fusion rescues the ability of 6KR to activate IFN-b reporter in vivo. Expression vectors for indicated proteins were transfected into HEK293T cells
with IFN-b-luciferase reporter. Cell lysates were assayed for luciferase activity (top) or pulled downwith glutathione Sepharose and immunoblotted (bottom). Error
bars represent variation range of duplicate experiments.
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Figure 5. Polyubiquitin Binding Induces Oligomerization of RIG-I and MDA5 CARD Domains
(A–D) RIG-I(N) (no GST tag) was incubated with K63-linked ubiquitin chains of indicated lengths and then fractionated by Superdex-200 gel filtration column.
Aliquots of the fractions were analyzed in IRF3 activation assays (top) and visualized by Coomassie blue-stained SDS-PAGE (bottom).
(E) RIG-I(N) was incubated with ubiquitin and then analyzed by Superdex-200 gel filtration column. Fractions were visualized by SDS-PAGE and Coomassie blue
staining.
(F) Varying concentrations of RIG-I(N)/Ub4 complex (lane 5 in Figure 5B) were tested in IRF3 dimerization assays. Signal intensity on native gel was quantified by
ImageQuant. Results from duplicated experiments are shown.
(G) MDA5(N) and K63-Ub6, separate or mixed, were analyzed by Superdex-200 gel filtration column. Aliquots of the fractions from indicated samples were
analyzed by immunoblotting. The fractions from the mixture of MDA5 and K63-Ub6 were also assayed for their ability to stimulate IRF3 dimerization (bottom).
Error bars represent variation range of duplicate experiments.
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Mechanism of RIG-I and MDA5 Activation by Ubiquitincells infected with SeV or uninfected. The RIG-I protein was
fractionated by gel filtration chromatography (Figure 7B). RIG-I
from uninfected cells eluted from the column with an elution
profile suggestive of a monomer (lanes 11 and 12). Although
the majority of RIG-I from the virus-infected cells also eluted as968 Immunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc.a monomer that was incapable of activating IRF3, a small frac-
tion eluted as HMW complexes that potently activated IRF3
(lanes 3–8). The heterogeneity of these active complexes may
reflect RIG-I tetramers bound to heterogeneous viral RNA and
ubiquitin chains in cells.
Figure 6. K63 Polyubiquitin Chains Induce the Formation of RIG-I Tetramer
(A) Analytical ultracentrifugation experiments of RIG-I(N) and K63-Ub3, alone (upper panel) or together (bottom panel), were performed. Absorbance at 280 nm
and Rayleigh interferometry results were analyzed with SEDPHAT. Sedimentation coefficient distribution of either RIG-I(N) or K63-Ub3 is shown on the same
graph for comparison.
(B–D) Similar to (A), RIG-I(N) and K63 ubiquitin chains of indicated lengths, alone or together, were analyzed by analytical ultracentrifugation. Calculated molar
masses and indicated molar ratios are shown for indicated peaks. Results shown are representatives of three experiments.
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Figure 7. RNA and Polyubiquitin Chains Induce Oligomerization of Full-Length RIG-I
(A) RIG-I was incubated with ATP, RNA and/or K63-Ub6 as indicated. The mixtures were fractionated with Superdex-200 gel filtration column. Aliquots of the
fractions were analyzed by immunoblotting and IRF3 dimerization assay as indicated. Only RIG-I incubated with ATP, RNA, and K63-Ub6 had IRF3 stimulatory
activity (bottom, and data not shown).
(B) HEK293T cells stably expressing RIG-I-Flag were infected with SeV or uninfected. RIG-I-Flag was affinity purified and analyzed by gel filtration with Superdex-
200 column. Aliquots of the fractions were analyzed by immunoblotting and in vitro IRF3 dimerization assay.
(C) Ubc13fl/fl primary MEF cells were infected with a lentiviral vector expressing RIG-I-Flag, then the Ubc13 gene was deleted with Cre recombinase or left intact
(±Cre). The cells were infected with SeV, and then RIG-I was affinity purified and tested for its ability to activate IRF3 dimerization (top). The efficiency of Ubc13
depletion was verified by immunoblotting (bottom).
(D) WT and Ubc13-deleted MEF cells (±Cre) were infected with SeV or not infected and then RIG-I was affinity purified and fractionated on a Superdex-200
column and subsequently immunoblotted.
(E) The fractions from RIG-I isolated from the virus-infected WT MEFs as shown in (D) (Cre, +SeV) were analyzed for their ability to stimulate IRF3 dimerization.
Results shown are representatives of two experiments.
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Mechanism of RIG-I and MDA5 Activation by UbiquitinWe performed two sets of experiments to investigate the role
of ubiquitination in RIG-I oligomerization in cells in response to
viral infection. First, we obtained primary MEFs from Ubc13
floxed/floxed (Ubcfl/fl) mice and deleted theUbc13 gene by using
a lentivirus expressing the Cre recombinase (Figures 7C–7E). To
facilitate the isolation of the RIG-I complex, these cells were also
engineered to stably express full-length RIG-I-Flag. The isolated
RIG-I complex from SeV-infected cells strongly activated IRF3 in
the in vitro reconstitution assay, but this activity was abolished in
cells expressing Cre, which depleted Ubc13 (Figure 7C). Impor-
tantly, when analyzed by gel filtration, a fraction of RIG-I isolated
from SeV-infected cells eluted from the column as HMW com-
plexes (Figure 7D). Only these complexes, but not the lower
molecular weight forms of RIG-I, were capable of activating
IRF3 (Figure 7E). Depletion of Ubc13 prevented the formation
of the HMW RIG-I complexes when cells were infected with
SeV (Figure 7D, lower panel). These results indicate that Ubc13970 Immunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc.is essential for RIG-I oligomerization in virus-infected cells,
implying that K63 polyubiquitination is important in this process.
In the second set of experiments, we reconstituted RIG-I
knockout MEFs with WT or ubiquitin-binding defective mutants
of RIG-I (K164A and 6KR; Figure S5D). SeV infection of cells re-
constituted with WT RIG-I led to the formation of HMW RIG-I
complexes capable of activating IRF3. In contrast, neither
K164A nor 6KR RIG-I was able to form HMW complexes in
virus-infected cells. Thus, the ability of RIG-I to bind K63 polyu-
biquitin chains is important for its oligomerization and activation
in response to viral infection.
DISCUSSION
In this study, we established a cell-free system in which MDA5
led to the activation of IRF3 in a manner that depends on binding
to poly[I:C] and K63 polyubiquitin chains. We showed that MDA5
Immunity
Mechanism of RIG-I and MDA5 Activation by UbiquitinCARD domains bind to K63 polyubiquitin chains and that this
binding is important for IRF3 activation. We have identified
several conserved residues within MDA5 and RIG-I CARD
domains that are required for K63 polyubiquitin chain binding.
Mutations that disrupt ubiquitin binding also impair the ability
of RIG-I and MDA5 to activate IRF3 and induce IFN-b. Collec-
tively, these results provide a unified mechanism of RIG-I and
MDA5 signaling that involves the binding of K63 polyubiquitin
chains through the tandem CARD domains.
We have carried out an extensive bioinformatics analysis of
proteins harboring known and putative domains belonging to
the death domain superfamily, including the CARD domains.
We grouped these proteins on the basis of their sequence
homology and available structural information. We have tested
several CARD domains for their ability to bind K63 polyubiquitin
chains, but so far only closely related RIG-I and MDA5 tandem
CARD domains have the ubiquitin binding activity. This limited
analysis by no means rules out the possibility that some other
domains of the DD superfamily could be functional ubiquitin
binding domains. Nevertheless, it appears that the CARD
domains of RIG-I and MDA5 have acquired the new ubiquitin-
binding function and utilize the labile ubiquitin chains as an
endogenous ligand to regulate their signaling functions.
Several lines of evidence strongly suggest that unanchored,
rather than substrate-anchored, ubiquitin chains activate RIG-I
and MDA5 in vitro and in cells: (1) unanchored K63 ubiquitin
chains containing more than two ubiquitin directly bind and acti-
vate the CARDdomains of RIG-I andMDA5 (here and Zeng et al.,
2010); this binding in full-length RIG-I and MDA5 is regulated by
RNA binding. In contrast, when ubiquitin chains are conjugated
to protein targets such as TRIM25 or TRAF6, they fail to activate
RIG-I or MDA5 (Zeng et al., 2010; X.J. and Z.J.C., data not
shown); (2) a large collection of point mutations in the CARDs
of RIG-I and MDA5 that disrupt their binding to K63 ubiquitin
chains also impair their ability to activate IRF3 in vitro and to
induce IFN-b in cells, indicating the importance of polyubiquitin
binding by RIG-I and MDA5; (3) although a very small fraction
of RIG-I is ubiquitinated in cells, removal of the ubiquitin chains
using a viral deubiquitination enzyme does not impair the ability
of RIG-I to activate IRF3 (Zeng et al., 2010); (4) a RIG-I mutant
that can bind to ubiquitin but cannot be ubiquitinated was
capable of inducing IFN-b in cells, suggesting that covalent ubiq-
uitination of RIG-I is dispensable for its function (Zeng et al.,
2010); (5) MDA5 does not contain a conserved lysine for ubiqui-
tination and there is no evidence that MDA5 is ubiquitinated in
cells; (6) fusion of the ubiquitination-defective mutants of RIG-I
and MDA5 to a heterologous ubiquitin binding domain (NZF)
restores IRF3 activation in vitro and IFNb induction in cells; and
(7) both RIG-I and MDA5 bind to endogenous unanchored K63
polyubiquitin chains, which can be isolated from human cells
and shown to potently activate the RIG-I pathway (here and in
Zeng et al., 2010). Despite such evidence, we cannot rule out
the possibility that an unknown ubiquitination targetmay activate
RIG-I or MDA5 in certain signaling pathway.
Our previous study shows that unanchored K63 polyubiquitin
chains generated by TRAF6 can activate TAK1 and IKK in the
IL-1 pathway (Xia et al., 2009). This raises the question of how
these ubiquitin chains achieve specificity in regulating distinct
signaling pathways. A possible solution to this question lies inthe fact that unanchored K63 ubiquitin chains are rapidly disas-
sembled by abundant deubiquitination enzymes in cells. Thus,
the ubiquitin chains may be delivered locally from the chain
generator (E3s such as TRIM25 or TRAF6) to the receptor (e.g,
RIG-I or TAB2) to initiate signaling; excess ubiquitin chains are
degraded. As TRIM25 and TRAF6 are recruited to RIG-I and
IL-1 receptor complex in response to virus infection and IL-1
stimulation, respectively, distinct signaling cascades are acti-
vated. Such temporal regulation and compartmentalization is a
hallmark of other intracellular signaling molecules, such as
cAMP and calcium, which are known to bind multiple cellular
targets but regulate distinct signaling pathways in response to
specific ligands.
Importantly, we demonstrated that the binding of K63 polyubi-
quitin chains leads to the formation of RIG-I tetramer, which is
highly potent in activating MAVS and the downstream pathway.
To our knowledge, this is the first example of ubiquitin binding
leading to protein oligomerization. We also observed oligomeri-
zation of full-length RIG-I that is dependent on RNA, ATP, and
K63 polyubiquitin chains. Further, virus infection leads to the
formation of a HMW RIG-I complex, and only this complex, but
not the lower-molecular-weight forms of RIG-I, is capable of acti-
vating IRF3 in the cell-free system. On the basis of these results,
we propose that sequential binding of RIG-I to viral RNA and
endogenous K63 polyubiquitin chains leads to its oligomeriza-
tion and subsequent activation. The oligomerization of RIG-I
probably promotes the formation of CARD domain clusters,
which presumably interact with the CARD domain of MAVS on
the mitochondrial surface, leading to MAVS aggregation and
activation.
Interestingly, we found that the stoichiometry of the RIG-I-
ubiquitin chain complex is 4:4 irrespective of ubiquitin chain
length, as long as the ubiquitin chains contain more than two
ubiquitins linked through K63. It is tempting to speculate that
individual ubiquitin in a chain bind to one or both of the tandem
CARD domains, and the longer ubiquitin chains may actually
‘‘chain’’ or ‘‘crosslink’’ different RIG-I CARD domains together.
Alternatively, the binding of K63 ubiquitin chains may induce
a conformational change of the RIG-I CARD domains to promote
their intermolecular interactions, resulting in their oligomeriza-
tion. High-resolution structural studies are required for under-
standing how ubiquitin chains bind to RIG-I CARD domains,
how the oligomerization occurs, and how it terminates to pro-
duce RIG-I tetramers. The formation of HMW RIG-I complex is
also detected in virus-infected cells and only these complexes
are capable of activating IRF3. Importantly, deletion of Ubc13
and a mutation that disrupts ubiquitin binding of RIG-I abolished
the formation of the HMW RIG-I complex, strongly suggesting
that K63 polyubiquitin chains are important for the activation of
RIG-I, probably by inducing its oligomerization. Further work is
needed to determine the composition and stoichiometry of the
active RIG-I complex isolated from virus-infected cells.
It remains to be determined how RIG-I oligomers become
competent to activate MAVS. We have been unable to detect
stable interaction between the CARD domains of RIG-I and
that of MAVS in the presence or absence of K63 polyubiquitin
chains. Interestingly, we recently found that incubation of sub-
stoichiometric amounts of RIG-I-ubiquitin chain complex with
mitochondria causes very rapid aggregation and activation ofImmunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc. 971
Table 1. Fixed IF Signal Increments and Refined ABS Signal
Increments Used in This Study






εIF = 2.75Mc (Mc is the calculated molar mass.)
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Mechanism of RIG-I and MDA5 Activation by UbiquitinMAVS on the mitochondrial membrane through a prion-like
mechanism (Hou et al., 2011). The aggregated forms of MAVS
are highly potent in activating IKK and TBK1, resulting in robust
production of type I interferons. Virus infection causes a nearly
complete conversion of full-length MAVS into the aggregate
forms, whereas only a small fraction of RIG-I forms active
HMW complexes after virus infection. Thus, MAVS CARD is
prone to form prion-like aggregates whereas RIG-I CARDs
tend to form a defined oligomer (tetramer in the presence of
ubiquitin chains). We hypothesize that the RIG-I-ubiquitin chain
complex acts like a catalyst in that it transiently contacts and
induces the aggregation of MAVS CARD, which in turn interacts
with other MAVS to form functional aggregates. This mechanism
allows for a rapid amplification of the signaling cascade upon




Biochemical assays for IRF3 activation with cytosolic extract (S5) and crude
mitochondria (P5) of cultured cells were described previously (Zeng et al.,
2009). In brief, hypotonic buffer (10 mM Tris-HCl [pH 7.5], 10 mM KCl,
1.5 mM MgCl2, 0.5 mM EGTA, and protease inhibitor cocktail) was used for
making S5, and isotonic buffer (hypotonic buffer plus 0.25 M D-Mannitol)
was used for making P5. Cells were homogenized in appropriate buffers and
centrifuged at 1,000 g for 5 min to pellet nuclei. Postnuclear supernatant
was further centrifuged at 5,000 g for 10min so that P5 and S5were separated.
P5waswashed oncewith isotonic buffer. For IRF3 pathway activation by RIG-I
or MDA5, proteins to be tested were added to reaction mixture containing
0.5 mg/ml P5, 3 mg/ml S5, 1xMgATP buffer (20 mM HEPES-KOH [pH 7.4],
2 mM ATP, 5 mM MgCl2), and
35S-IRF3. After incubation at 30C for 1 hr,
samples were centrifuged at 20,000 g for 5 min and supernatants were sub-
jected to native PAGE for visualizing IRF3 dimerization by autoradiography
with PhosphorImager (GE Healthcare). ImageQuant was used for quantifying
signal intensity.
Biochemical Assay for RIG-I and MDA5 Activation In Vitro
For RIG-I(N) or MDA5(N) activation by ubiquitination, RIG-I(N) or MDA5(N) was
subjected to ubiquitination reaction, and then 1 ml of the reaction mixture was
used in IRF3 activation assay described above. For RIG-I(N) or MDA5(N) acti-
vation by ubiquitin chains, 1 ml mixture containing 50 ng of RIG-I(N) or MDA5(N)
and 50 ng of ubiquitin chain was incubated at 4C for 30 min, and then tested
in IRF3 activation assay. Five-fold serial dilution was used in titration ex-
periments. For standard activation assays of full-length RIG-I or MDA5, 1 ml
mixture containing 50 ng of RIG-I or MDA5, 50 ng poly[I:C] or 50-pppRNA,
50 ng ubiquitin chains, in the presence of 1xMgATP buffer, was incubated at
4C for 30 min, and then used in IRF3 activation assay.
Analytical Ultracentrifugation
Multisignal sedimentation velocity (SV) experiments were carried out as
described in (Padrick et al., 2010). In brief, concentrated stocks of RIG-I(N),
K63-Ub3, -Ub4, -Ub5, and -Ub6 were prepared in 20 mM Tris-HCl (pH7.5),
20 mM NaCl, 0.5 mM TCEP, and diluted in the same buffer to final concentra-
tions of 4-8 mM for RIG-I(N) or 20-40 mM for K63-Ub chains, separate or in
combination. Samples were allowed to equilibrate for 16 hr at 4C, and loaded
into centrifugation cells equipped with charcoal-filled Epon centerpieces and
sapphire windows; the cells were allowed to equilibrate at 20C for two hours
before centrifugation. 390 ml of sample in the sample sector and the same
volume of buffer without proteins in the reference sector were centrifuged
with Beckman Optima XL-I analytical ultracentrifuge in an An50Ti rotor at
50,000 rpm or 35,000 rpm, at 20C, until all components apparently sedi-
mented to the bottom of the cell. We collected UV absorbance at 280 nm
(ABS) and Rayleigh interferometry (IF) data simultaneously with the Beckman
control software and analyzed them with SEDPHAT using multiwavelength972 Immunity 36, 959–973, June 29, 2012 ª2012 Elsevier Inc.model (Balbo et al., 2005). Molar signal increments (ε) of all components
were calculated (εIF) or refined by SEDPHAT from experimental data (εABS),
shown in Table 1. All values for buffer densities, buffer viscosities, and partial
specific volumes of the proteins were estimated with SEDNTERP.
RIG-I Oligomerization Analysis by Gel Filtration
For RIG-I in vivo oligomerization experiments, HEK293T cells stably express-
ing RIG-I-Flag (Chiu et al., 2009) were infected with SeV or mock treated for
16 hr. For MEF cells stably expressing RIG-I-Flag, cells were infected with
SeV or mock treated for 10 hr. Cell lysates were prepared in lysis buffer
(20 mM Tris-HCl [pH 7.5], 150 mMNaCl, 0.5%NP40, 1 mMDTT, and protease
inhibitor cocktail). RIG-I was immunoprecipitated from cell lysates with anti-
Flag M2-agarose at 4C for 2 hr. The agarose beads were washed three times
with lysis buffer, and RIG-I was eluted with 0.2 mg/ml Flag peptide in Buffer A
(20 mM Tris-HCl [pH 7.5] and 1 mM DTT). For RIG-I in vitro oligomerization
experiments, RIG-I (0.1 mg/ml) was incubated in various combinations with
ATP (provided as 1xMgATP buffer), 50-pppRNA (0.1 mg/ml), and K63-Ub6
(1 mg/ml) in Buffer B (20 mM Tris-HCl [pH 7.5], 100 mM NaCl, and 0.5 mM
TCEP) at 4C for 30 min. Fifty microliters of each sample was subjected to
Superdex-200 gel filtration analysis with Buffer B as the elution buffer.
For RIG-I(N) oligomerization experiments, RIG-I(N) (0.5 mg/ml) was incu-
bated with K63-Ub3, -Ub4, -Ub5, or -Ub6 (0.5 mg/ml) at 4C for 30 min. For
MDA5(N) oligomerization experiments, MDA5(N) (0.05 mg/ml) was incubated
with K63-Ub6 (2 mg/ml) at 4C for 30 min. Fifty microliters of each mixture
was loaded onto Superdex-200 gel filtration columnwith Buffer A. Gel filtration
fractions were used for immunoblotting and IRF3 activation assay. For
semiquantification, fractions containing RIG-I(N):Ub chain complexes were
subjected to SDS-PAGE alongside purified RIG-(N) and Ub chains mixed at
defined ratio, then stained with Coomassie blue. Gel band intensities were
quantified with ImageQuant.
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